ArticleOncotarget2017
Long noncoding RNA MALAT-1 is a novel inflammatory regulator in human systemic lupus erythematosus.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Pooled it
- Long Non-coding RNAs Genes Polymorphisms and Their Expression Levels in Patients With Rheumatoid Arthritis.Frontiers in immunology · 2019Trial
- The Role of Non-coding RNAs in Connective Tissue Diseases: Diagnostic and Therapeutic Potential of miRNAs, lncRNAs and circRNAs.Molecular diagnosis & therapy · 2026Review
- Aberrant STAT3 activation and overproduction of IL-21 in systemic lupus erythematosus: role of miR-155 and miR-21 in target genesFrontiers in immunology · 2026Article
- SIRT1 as a Key Regulator in Rheumatic Diseases: Integrating Molecular Insights with Traditional Chinese Medicine Approaches.Journal of inflammation research · 2026Review
- Deciphering the enigma: long noncoding RNAs in disease pathogenesis and therapeutic prospects.Molecular and cellular biochemistry · 2025Review
- RNA-Seq analysis reveals the long noncoding RNAs associated with immunity in wild Myotis myotis bats.BMC genomics · 2025Article
- Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology.PloS one · 2025Article
- circ_0046599 Promotes HCC Progression by Competing with miR-1322 to Enhance NT5DC2 Expression.Journal of Cancer · 2025Article
- The diagnostic and predictive potential of lncRNA CASC2 targeting miR-155 in systemic lupus erythematosus patients with nephritis complication.Scientific reports · 2024Article
- Review
- MALAT1 predicts the prognosis of severe community-acquired pneumonia in pediatric patients.BMC pulmonary medicine · 2024Article
- Identification and bioinformatics analysis of lncRNAs in serum of patients with ankylosing spondylitis.BMC musculoskeletal disorders · 2024Review
- Novel potential lncRNA biomarker in B cells indicates essential pathogenic pathway activation in patients with SLE.Lupus science & medicine · 2024Article
- The Expression Patterns and Implications ofInternational journal of molecular sciences · 2023Article
- Long non-coding RNAs ANRIL, THRIL, and NEAT1 as potential circulating biomarkers of SARS-CoV-2 infection and disease severity.Virus research · 2023Article
- Urinary Long Non-Coding RNA Levels as Biomarkers of Lupus Nephritis.International journal of molecular sciences · 2023Article
- The emerging role of noncoding RNAs in systemic lupus erythematosus: new insights into the master regulators of disease pathogenesis.Therapeutic advances in chronic disease · 2023Review
- Article
- Long Intergenic Noncoding RNAs Affect Biological Pathways Underlying Autoimmune and Neurodegenerative Disorders.Molecular neurobiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite growing evidence that Long noncoding RNAs (lncRNAs) can regulate gene expression and widely take part in autoimmune and inflammatory diseases, our knowledge of systemic lupus erythematosus (SLE)-related lincRNAs remains limited. In this study, we aimed to explore the contribution of the lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) to the pathogenesis of SLE. PBMCs were obtained from SLE patients and healthy donors. The expression levels of MALAT-1 were measured by quantitative PCR. Small interfering RNA (siRNA) was then used to knock down the expression of MALAT1 in order to determine the role of MALAT1 in the expression levels of IL-21 and SIRT1 signaling pathway in primary monocytes of SLE patients. Here, we found MALAT-1 expression was abnormally increased in SLE patients and predominantly expressed in human monocytes. Additionally, silencing MALAT-1 significantly reduced the expression of IL-21 in primary monocytes of SLE patients. Furthermore, MALAT-1 exerts its detrimental effects by regulating SIRT1 signaling. Our results demonstrate that MALAT-1 is the key regulatory factor in the pathogenesis of SLE and provides potentially novel target for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.